Flosequinan, a vasodilator with a novel mechanism of action
- PMID: 1855126
- PMCID: PMC1917979
- DOI: 10.1111/j.1476-5381.1991.tb12286.x
Flosequinan, a vasodilator with a novel mechanism of action
Abstract
1. The mechanism of action of flosequinan was investigated in ferret aortic smooth muscle by the simultaneous measurement of aequorin luminescence and isometric force. 2. The control calcium-force curve was obtained by plotting the calibrated aequorin luminescence against the force from potassium-depolarized muscles. Flosequinan relaxed potassium-depolarized muscles by causing parallel changes in [Ca2+]i and force with no shift in the control [Ca2+]i-force relationship. 3. The [Ca2+]i-force relationship in the presence of a maximally effective concentration of phenylephrine was significantly shifted to the left of that for the control, potassium-depolarized muscle. Flosequinan relaxed the phenylephrine-contracted muscle by causing a large decrease in force with only a minimal decrease in [Ca2+]i, resulting in an apparent rightward shift of the [Ca2+]i-force relationship, toward the control curve. 4. In comparison, sodium nitroprusside caused relaxation of either the potassium- or phenylephrine-induced contraction solely by a decrease in [Ca2+]i with no shift in either calcium-force relationship. 5. Milrinone caused no significant rightward shift of the calcium-force relationship during phenylephrine- or potassium-induced contractions, but when milrinone was added in the absence of vasoconstrictors, relaxation was obtained with no significant decrease in [Ca2+]i. 6. Flosequinan appears to differ in mechanism of action from both nitroprusside and milrinone. It relaxes depolarization-mediated contractions solely by decreasing [Ca2+]i but also appears to be capable of reversing the apparent calcium sensitizing action of phenylephrine.
Similar articles
-
Involvement of the protein kinase C system in calcium-force relationships in ferret aorta.Br J Pharmacol. 1989 Jun;97(2):391-400. doi: 10.1111/j.1476-5381.1989.tb11966.x. Br J Pharmacol. 1989. PMID: 2758222 Free PMC article.
-
Mechanisms of positive inotropic action of flosequinan, hydralazine, and milrinone on mammalian myocardium.Eur J Pharmacol. 1997 Feb 26;321(2):201-8. doi: 10.1016/s0014-2999(96)00946-6. Eur J Pharmacol. 1997. PMID: 9063689
-
Calcium-force relationships as detected with aequorin in two different vascular smooth muscles of the ferret.J Physiol. 1985 Dec;369:269-82. doi: 10.1113/jphysiol.1985.sp015900. J Physiol. 1985. PMID: 4093883 Free PMC article.
-
Pharmacology of flosequinan.Am Heart J. 1991 Mar;121(3 Pt 1):974-83. doi: 10.1016/0002-8703(91)90229-b. Am Heart J. 1991. PMID: 2000776 Review.
-
Flosequinan.Lancet. 1993 Mar 20;341(8847):733-6. doi: 10.1016/0140-6736(93)90498-6. Lancet. 1993. PMID: 8095635 Review. No abstract available.
Cited by
-
Flosequinan does not affect systemic and regional vascular responses to simulated orthostatic stress in healthy volunteers.Br J Clin Pharmacol. 1992 Sep;34(3):207-14. doi: 10.1111/j.1365-2125.1992.tb04126.x. Br J Clin Pharmacol. 1992. PMID: 1389945 Free PMC article. Clinical Trial.
-
Differential inotropic effects of flosequinan in ventricular muscle from normal ferrets versus patients with end-stage heart failure.Br J Pharmacol. 1992 Jul;106(3):511-6. doi: 10.1111/j.1476-5381.1992.tb14367.x. Br J Pharmacol. 1992. PMID: 1324072 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous